News

The IL-17A inhibitor did not meet its phase 2b/3 clinical trial primary end point.

The submission follows the announcement of recent long-term data of the drug in patients ages 6 years and older.

Discover how we continue to spotlight innovation and remain curious with the goal to help you improve patient outcomes.

Share your insights ahead of October's National Eczema Awareness Month by emailing our team at [email protected].

The FDA no longer restricts the donation of human cells, tissues, cellular or tissue-based products, human milk, ova, sperm, or organs for transplantation for patients who receive StrataGraft.

Steven Dayan, MD, FACS, first author behind a recent study involving high rates of patient satisfaction following treatment with botulinum toxin, discusses the importance of placing patient satisfaction at the forefront of cosmetic dermatology.

Rescue workers had a higher rate of malignant melanoma between 2005 and 2015 compared the general population of New York State.

As deucravacitinib surpasses its 1-year milestone since approval, clinicians continue to monitor its real-world performance among patients.

This Alopecia Awareness Month, we want to know your thoughts on necessary action points to improve alopecia awareness. Click here to answer this week's poll.

Stress from dermatologic conditions can create or magnify psychiatric illness.

Keep up with the latest headlines in dermatology from the past week, including awareness efforts following singer Jimmy Buffett's death from complications of Merkel cell carcinoma, AI dermatology tools lacking representation of darker skin tones, and more.

ICYMI, this week we had articles about acne vulgaris management from an expert panel, a look back at summer dermatology conferences, long-term results of roflumilast cream 0.15% for AD, and more.

Second-line end points of the TRICOTEL trial assessing atezolizumab plus vemurafenib and cobimetinib in melanoma with central nervous system metastases appear consistent with primary efficacy end points.

The physician-owned practice combines residency and Mohs fellowship programs with patient care.

This week’s collection of the latest dermatologic studies covers the hair regrowth cycle in mice, considering large language models in dermatology, cutaneous leiomyosarcomas subtypes, and the efficacy of tralokinumab in older adults with atopic dermatitis.

Topical minoxidil combined with oral spironolactone significantly improved hair density.

The condition may present as a manifestation of pediatric rosacea.

Recipients of the IFundWomen grant kicked off crowdfunding campaigns to grow their businesses.

BTA treatment was both safe and effective in male and female patients, indicating its potential as a therapeutic strategy in treating Egyptian patients with AGA.

Significant improvement was shown in erythema and pruritis and patients reported high satisfaction.

A coprimary end point in the phase 3 LEAP-010 study will not be met.

Roflumilast maintained disease control when patients switched to twice-weekly dosing.

The review found that utilizing dupilumab to treat these patients with AD cost more than using baricitinib, although dupilumab was more effective.

As we approach National Eczema Week and National Eczema Month, take a look at the most influential atopic dermatitis research from the last decade.

Perifollicular infundibulo-isthmic lymphocytoplasmic infiltrates and fibrosis appeared in all patients, regardless of ethnicity.

Patients treated by rheumatologists were more often treated with tumor necrosis factor inhibitors.

Click here to answer this week's skin cancer poll.

A panel of 9 dermatologists met and created 5 statements regarding the role of ceramide-containing skin care products in reducing skin barrier dysfunction related to acne treatments.

The VIOLIN study examined the burden of disease, prevalence, and treatment of vitiligo in patients in France.